Literature DB >> 623127

Toxicity of D-penicillamine in rheumatoid arthritis. A report of 63 patients including two with aplastic anemia and one with the nephrotic syndrome.

A S Weiss, J A Markenson, M S Weiss, W H Kammerer.   

Abstract

To assess toxicity of D-penicillamine a retrospective chart review was performed on 63 patients with rheumatoid arthritis receiving penicillamine. These patients had a total of 83 courses of therapy. The mean age of patients was 52 years and the mean duration of disease was 10.07 years. Laboratory data showed an increase in hematocrit values from 36 per cent to 40 per cent and a decrease in the erythrocyte sedimentation rate from an average of 50 to 29 mm/hour. The platelet count also decreased with treatment from 394,000 to 267,000/mm3. The over-all complication rate was 53 per cent. Life-threatening complications occurred in two patients including one case of aplastic anemia and one case of nephrotic syndrome. One additional patient was referred with aplastic anemia. Minor complications include rash in 18 per cent, loss of taste in 6 per cent, dyspepsia in 11 per cent, oral ulceration in 7 per cent and proteinuria of less than 3 g/day in 8 per cent. In summary, 53 per cent of the courses of penicillamine were associated with toxicity including one episode of aplastic anemia and one case of nephrotic syndrome. Therapy was stopped due to complications in 39 per cent of the patients in this series.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 623127     DOI: 10.1016/0002-9343(78)90186-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.

Authors:  Haruki Kondo; Kanae Narita
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

2.  Cholestasis associated with d-penicillamine therapy for rheumatoid arthritis.

Authors:  B D McLeod; T D Kinsella
Journal:  Can Med Assoc J       Date:  1979-04-21       Impact factor: 8.262

3.  Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis.

Authors:  L Kandola; A J Swannell; A Hunter
Journal:  Ann Rheum Dis       Date:  1995-06       Impact factor: 19.103

4.  Does the order of second-line treatment in rheumatoid arthritis matter?

Authors:  M M Steven; J A Hunter; R M Murdoch; H A Capell
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-09

Review 5.  Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases.

Authors:  I A Jaffe
Journal:  Springer Semin Immunopathol       Date:  1981

6.  Myelotoxicity of D-penicillamine.

Authors:  A G Kay
Journal:  Ann Rheum Dis       Date:  1979-06       Impact factor: 19.103

7.  A case of focal segmental glomerulosclerosis associated with aplastic anemia.

Authors:  Chi Young Park; Dong Min Kim; Young Sin Cho; Sung Ho Yoon; Jong Hoon Chung; Choon Hae Chung; Hyun Lee Kim
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

8.  D-penicillamine in pregnancy--to ban or not to ban?

Authors:  W Endres
Journal:  Klin Wochenschr       Date:  1981-06-01

Review 9.  Remission-inducing drugs in rheumatoid arthritis.

Authors:  T P Anastassiades
Journal:  Can Med Assoc J       Date:  1980-02-23       Impact factor: 8.262

10.  Fatal aplastic anaemia and liver toxicity caused by D-penicillamine treatment of rheumatoid arthritis.

Authors:  B Fishel; M Tishler; D Caspi; M Yaron
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.